Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

remove_circle_outline

Search Results (1)

Search Parameters:
Keywords = Clostridioides diffcile infections

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
14 pages, 680 KiB  
Review
Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections
by Ahran Lee, Jung Sik Yoo and Eun-Jeong Yoon
Antibiotics 2024, 13(10), 995; https://doi.org/10.3390/antibiotics13100995 - 20 Oct 2024
Cited by 2 | Viewed by 3147
Abstract
Clostridioides difficile is a major causative pathogen for antibiotic-associated diarrhea and C. difficile infections (CDIs) may lead to life-threatening diseases in clinical settings. Most of the risk factors for the incidence of CDIs, i.e., antibiotic use, treatment by proton pump inhibitors, old age, [...] Read more.
Clostridioides difficile is a major causative pathogen for antibiotic-associated diarrhea and C. difficile infections (CDIs) may lead to life-threatening diseases in clinical settings. Most of the risk factors for the incidence of CDIs, i.e., antibiotic use, treatment by proton pump inhibitors, old age, and hospitalization, are associated with dysbiosis of gut microbiota and associated metabolites and, consequently, treatment options for CDIs include normalizing the composition of the intestinal microbiome. In this review, with an introduction to the CDI and its global epidemiology, CDI-associated traits of the gut microbiome and its metabolites were reviewed, and microbiome-targeting treatment options were introduced, which was approved recently as a new drug by the United States Food and Drug Administration (U.S. FDA), rather than a medical practice. Full article
(This article belongs to the Special Issue Antibiotic-Associated Dysbiosis and Management)
Show Figures

Figure 1

Back to TopTop